Sign in

    Kenny Chan

    Senior Vice President and Equity Research Analyst at Jefferies

    Kenny Chan is a Senior Vice President and Equity Research Analyst at Jefferies, focusing on consumer and retail sectors with coverage of leading companies such as lululemon athletica, GAP, and Urban Outfitters. Renowned for his data-driven analysis, Chan has maintained analyst success rates around 65% and generated average returns exceeding 13% per recommendation based on third-party tracking platforms. He joined Jefferies in 2020 after prior roles at Barclays and J.P. Morgan, where he also specialized in retail equities research, and began his investment research career in 2010. Kenny holds FINRA Series 7, 63, 86, and 87 licenses and is recognized for actionable investment calls and industry expertise in apparel and specialty retail.

    Kenny Chan's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership

    Kenny Chan's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership • Q3 2020

    Question

    Kenny Chan, on for Maury Raycroft, asked about the potential for the post-hoc findings from the systemic sclerosis trial to be incorporated into an FDA label and whether new trials would be required. He also inquired about feedback from the cystic fibrosis community and if the decision to shorten the dermatomyositis trial was influenced by competitor data or efficacy read-through from the other failed trials.

    Answer

    Chief Medical Officer and Head of Research, Barbara White, clarified that the completed Phase 3 systemic sclerosis study is not considered adequate for regulatory approval and that a new Phase 3 study would be necessary to move forward. Regarding cystic fibrosis, she stated that while conversations are ongoing, failing to meet a primary endpoint generally precludes a trial from being used as the basis for approval. Dr. White confirmed the decision to shorten the dermatomyositis trial was driven by an assessment of competitor trial durations, making it a strategic adjustment rather than a reaction to data from the SSc or CF studies.

    Ask Fintool Equity Research AI